The Republic of Korea acknowledges the fact that capitalism in pharmaceutical companies can augment the effects of antimicrobial resistance. Many of the new superbugs could actually be cured if these companies bothered to cure them, but they don't because they won't make enough profit. This is not to say that the pharmaceutical companies caused the resistance problem, but this is to say that they could possibly cure those infected people that may die without their medications. We suggest giving subsidies to the companies that combat resistant organisms. Any thoughts? Solutions?
2 posters
Importance of pharmaceutical companies
WHO_SouthKorea- Posts : 4
Points : 8
Join date : 2014-05-13
WHO_Finland- Posts : 3
Points : 3
Join date : 2014-05-15
Finland would like to ask the delegation of South Korea to provide evidence that these pharmaceutical companies have the resources to possibly find a "cure" for diseases. In addition to the points stated by South Korea, Finland would like to assume that pharmaceutical companies try to reduce the cost even further to make a bigger profit. A reminder that most of the diseases such as cancer, malaria, HIV and aids have not been cured yet.
WHO_SouthKorea- Posts : 4
Points : 8
Join date : 2014-05-13
Firstly, the Republic of Korea would like to point out that pharmaceutical companies make a LOT of money off of cancer medications. Also, considerable advances have been made to cute HIV, and a total cure of HIV in the future is possible. Secondly, since not many superbugs are global issues, there is not much money to be made from curing them, and since curing the superbugs may be more expensive to cure than regular "bugs", pharmaceutical companies wouldn't make as much money on them as they could from curing other diseases. To connect this to what the delegate of Finland said, these companies wouldn't make as much money on them, hence they wouldn't want to cure them. Finally, it is quite probable that cures exist to these superbugs, but that they haven't been found yet. Superbugs are resistant to existing antibiotics, not necessarily ones that could be discovered in the future.